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analysisThe health risks related to cigarette smoking are well known
and are dose-related: they increase with smoking duration and
daily cigarette consumption and decline following smoking cessa-
tion (Doll et al., 1994; IARC, 2007). Historically, some countries
introduced regulations (European Union, 2001) to measure and re-
duce the tar yields of cigarettes as determined using machine-
smoking methods, such as that speciﬁed by the International Orga-
nization for Standardization (ISO, 2000) (and previously by the US
Federal Trade Commission (FTC, 1966, 1967)). It was always con-
sidered that while machine smoking of cigarettes may be useful
for design and regulatory purposes it cannot represent human
smoking behaviour and that smoking machine yield data are not
measurements of human exposure or risk (ISO, 2006). Despite this,
attempts have been made to identify alternative machine-smoking
regimes that may be more representative of human exposure
(Kozlowski and O’Connor, 2000), but the variability in human
smoking behaviour means that any machine method can, at best,
only be an indicator of relative human smoke exposure at the
population level and cannot be used for individual smokers.
Consequently, methodologies that provide accurate measures of
smokers’ exposure to smoke or smoke constituents are important
tools in studies of smokers’ behaviour and may have value in the
assessment of Modiﬁed Risk Tobacco Products (MRTPs) or Poten-
tial Reduced-Exposure Products (PREPs) as a proxy of exposure to
tobacco toxicants.
Ideally methods would be available that provide an absolute
measure of the ‘dose’ of smoke constituents to the smoker (where
dose is deﬁned as the amount of smoke constituent absorbed by
the body). However, such methods are not currently available
and researchers have to rely on estimates of smoke exposure. His-
torically, three approaches have been used to estimate human
smoke exposure from conventional cigarettes (Scherer, 1999;
Benowitz, 2001):
1. Pufﬁng topography and duplication
Human pufﬁng topography is recorded, followed by accurate
duplication of this record using a specialised smoking machine.
The cigarette smoke generated during duplication is trapped and
smoke constituents analysed. This approach provides an estimate
of the amount of smoke that entered the smoker’s mouth (mouth
level exposure or MLE) and, because it does not take into account
any post-puff behaviour (e.g. non-inhaled puffs, mouth spill and
post-puff exhalation of unretained smoke) represents an estimate
of the maximum potential exposure. In addition, the smoking re-
cords are generally obtained in a laboratory setting using a ciga-
rette holder, which can affect smoking behaviour (Comer and0273-2300  2011 Elsevier Inc.
doi:10.1016/j.yrtph.2011.11.005
Open access under CC BY-NC-ND license.Creighton, 1978; Ossip-Klein et al., 1983), and the smoke analysed
is derived from a different, but usually matched cigarette.
2. Biomarkers of exposure
Biomarkers of exposure in blood, urine and saliva may provide a
useful estimate of exposure to smoke constituents. Biomarkers
generally have wider acceptance as measures of exposure but the
proximity to ‘dose’ of the tobacco smoke constituent depends in
part on the fractional recovery and the speciﬁcity to the constitu-
ent. Namely, the greater the fractional recovery the lower is the
potential affect of metabolic variation; and the greater the speciﬁc-
ity, the lower is the potential for confounding inﬂuences and the
better the estimate of smoke constituent ‘dose’. In some cases
the biomarker is a single, minor metabolite that when combined
with metabolic variation between individuals and poor speciﬁcity,
would mean that the level of the biomarker can only be indicative
of relative dose. In other cases (e.g. nicotine) the biomarker is the
sum of the majority of metabolites and is speciﬁc to tobacco
smoke. This greater fractional recovery, uncontaminated by other
non-tobacco sources both reduces the inﬂuence of variability be-
tween individuals and provides a closer estimate of dose.
The collection of biomarkers is remote from the complex puff
and post-puff behavioural interactions and therefore may be more
representative of smoke constituent dose. However sample collec-
tion can be invasive possibly inﬂuencing behaviour, and biomarker
studies are expensive and better suited to small-to-medium sized
populations in a clinical environment.
3. Filter analysis
Filter analysis involves chemical analysis of spent cigarette
ﬁlters from cigarettes smoked by human subjects, followed by esti-
mation of the cigarette yield by reference to a calibration curve
generated by machine smoking cigarettes in the laboratory. As
for the duplication of pufﬁng topography, ﬁlter analysis also pro-
vides an estimate of the maximum amount of smoke that would
have entered the smokers mouth (MLE) (Baker and Dixon, 1998;
Feng et al., 2006; St. Charles et al., 2006) and does not take account
of inter-individual post-pufﬁng behaviour. However, ﬁlter analysis
methods are non-invasive, allowing natural smoking behaviour
with simple sample collection by large numbers of study partici-
pants, thus enabling an assessment of exposure on both an individ-
ual and population level. Filter analysis methods can be used to
estimate smoke exposure on a per cigarette or per day basis, are
capable of high throughput (Watson et al., 2004; Shepperd et al.,
2006) and have been shown to be sensitive and accurate (Shepperd
S2 Introduction / Regulatory Toxicology and Pharmacology 61 (2011) S1–S2et al., 2006). A review of cigarette ﬁlter-based assays as proxies for
toxicant exposure and smoking behaviour concluded that these
methods may have utility as proxy measures of mouth-level expo-
sure in clinical trials (Pauly et al., 2009).
The papers in this special issue demonstrate the range of appli-
cations to which ﬁlter analysis can be applied in order to estimate
smokers’ mouth-level exposure to smoke constituents. The papers
include relatively small numbers of subjects in clinical settings,
surveys of much larger numbers of smokers that are closer to being
representative of populations, and in studies to evaluate the im-
pact of regulatory changes to cigarettes or to the location where
cigarettes are smoked. Morin et al. have conﬁrmed earlier ﬁndings
by St.Charles et al. (2006) and Shepperd et al. (2009) by correlating
ﬁlter analysis estimates of nicotine exposure with biomarker esti-
mates using Canadian smokers and cigarettes (but found that a
gender bias inﬂuenced the outcome). Shepperd et al. demonstrate
that the correlation between exposure estimates from ﬁlter analy-
ses and biomarkers of exposure is maintained when the subjects
switch to a lower ISO tar yield product. Nelson et al. assessed
smoke exposure in 1330 US smokers and Mariner et al. generated
data from 5703 smokers in eight countries, including a number of
countries where no smoke exposure estimates previously existed.
Cote et al. used mouth level exposure estimates to assess the im-
pact of changes to cigarettes in Canada to comply with ignition
propensity regulations. Finally, Ashley et al. assessed the impact
of regulation preventing indoor smoking in public places in
Scotland.
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